Artikel ; Online: Management of congenital nephrotic syndrome: consensus recommendations of the ERKNet-ESPN Working Group.
2021 Band 17, Heft 4, Seite(n) 277–289
Abstract: Congenital nephrotic syndrome (CNS) is a heterogeneous group of disorders characterized by nephrotic-range proteinuria, hypoalbuminaemia and oedema, which manifest in utero or during the first 3 months of life. The main cause of CNS is genetic defects in ...
| Abstract | Congenital nephrotic syndrome (CNS) is a heterogeneous group of disorders characterized by nephrotic-range proteinuria, hypoalbuminaemia and oedema, which manifest in utero or during the first 3 months of life. The main cause of CNS is genetic defects in podocytes; however, it can also be caused, in rare cases, by congenital infections or maternal allo-immune disease. Management of CNS is very challenging because patients are prone to severe complications, such as haemodynamic compromise, infections, thromboses, impaired growth and kidney failure. In this consensus statement, experts from the European Reference Network for Kidney Diseases (ERKNet) and the European Society for Paediatric Nephrology (ESPN) summarize the current evidence and present recommendations for the management of CNS, including the use of renin-angiotensin system inhibitors, diuretics, anticoagulation and infection prophylaxis. Therapeutic management should be adapted to the clinical severity of the condition with the aim of maintaining intravascular euvolaemia and adequate nutrition, while preventing complications and preserving central and peripheral vessels. We do not recommend performing routine early nephrectomies but suggest that they are considered in patients with severe complications despite optimal conservative treatment, and before transplantation in patients with persisting nephrotic syndrome and/or a WT1-dominant pathogenic variant. |
|---|---|
| Mesh-Begriff(e) | Albumins/therapeutic use ; Antibiotic Prophylaxis ; Anticoagulants/therapeutic use ; Combined Modality Therapy ; Diuretics/therapeutic use ; Fluid Therapy ; Genetic Markers ; Genetic Testing ; Humans ; Infections/etiology ; Infections/therapy ; Nephrectomy ; Nephrotic Syndrome/complications ; Nephrotic Syndrome/diagnosis ; Nephrotic Syndrome/genetics ; Nephrotic Syndrome/therapy ; Thrombosis/etiology ; Thrombosis/prevention & control |
| Chemische Substanzen | Albumins ; Anticoagulants ; Diuretics ; Genetic Markers |
| Sprache | Englisch |
| Erscheinungsdatum | 2021-01-29 |
| Erscheinungsland | England |
| Dokumenttyp | Consensus Development Conference ; Journal Article ; Practice Guideline ; Research Support, Non-U.S. Gov't |
| ZDB-ID | 2490366-8 |
| ISSN | 1759-507X ; 1759-5061 |
| ISSN (online) | 1759-507X |
| ISSN | 1759-5061 |
| DOI | 10.1038/s41581-020-00384-1 |
| Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
| Zs.A 6334: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
|||
| Zs.MG 107: Hefte anzeigen |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.